The rollator industry is overdue for a transformation, says columnist Dagmar Munn, a longtime user of the device who is living with ALS.

A study is exploring why athletes, first responders, and other high performers face an increased risk of developing ALS.

The first patient has been dosed in a Phase 1/2 clinical study of VTx-002, an experimental therapy for amyotrophic lateral sclerosis.

A bipartisan team of U.S. lawmakers has reintroduced the ALS Better Care Act, aimed at improving access to quality medical ...

Scientists developed a technique to grow cells that control voluntary movement, a discovery that could aid ALS and spinal ...

Origami is collaborating with Ipsen to develop molecules designed to remove or correct abnormal proteins in neurodegenerative diseases.

Half of the planned 200 ALS patients have joined Medicinova’s expanded access program evaluating the experimental drug MN-166 ...

A viral infection can trigger a neurological disease similar to amyotrophic lateral sclerosis (ALS) in mice with a specific ...

Coya Therapeutics raised $11.1 million to support manufacturing scale-up for its experimental ALS therapy, COYA 302.

Watching dancers capture both grief and joy reminded columnist Kristin Neva of her own life as a caregiver to her husband, who has ALS.

Reducing RAD23A levels helped nerve cells better handle toxic TDP-43 protein clumps, improving survival and function in an ALS mouse model.

U.S. clinical trials for ALS do not include enough non-white patients and women to reflect the disease's real-world prevalence, per a study.